Comprehensive Treatment for Major Salivary Gland Carcinoma
Based on Intensity-Modulated Radiotherapy with or without Radical Surgery

Zichen Qiu
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Zheng Wu
Hunan Sheng Zhong Liu Yi Yuan: Hunan Cancer Hospital

Feifei Lin
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Lei Wang
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Dehuan Xie
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Wanqin Cheng
Shunde Hospital of Southern Medical University

Shaowen Lyu
Maastricht University Medical Centre+: Maastricht Universitair Medisch Centrum+

Xuekui Liu
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Mingli Wang
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Jiang Hu
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Yalan Tao
Sun Yat-sen University Affiliated Tumor Hospital: Sun Yat-sen University Cancer Center

Yong Su (✉ suyong@sysucc.org.cn)
Sun Yat-sen University Cancer Center  https://orcid.org/0000-0002-8888-8694

Research

Keywords: Intensity-modulated radiotherapy, Lymphoepithelial carcinoma, Major salivary gland carcinoma, Target volume delineation

Posted Date: November 11th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1042786/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

The present study aimed to determine a treatment strategy and Intensity-Modulated Radiotherapy (IMRT) target volume for major salivary gland carcinoma (SGC).

Methods

Patients with SGC treated at our cancer center between August 2009 and August 2020 were retrospectively reviewed.

Results

The following primary tumor sites were identified: parotid gland in 61 (69.3%) patients, submandibular gland in 21 (23.9%) patients, and sublingual gland in six (6.8%) patients. Lymphoepithelial carcinoma (LEC) was the most common tumor subtype that accounted for 23.9% of cases. A total of 80 (90.9%) patients received radical surgery combined with postoperative radiotherapy. Eight patients (9.1%) received definitive radiotherapy: six patients with advanced-stage disease received induction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT), and two patients with early-stage disease received CCRT. Complete response was observed in these eight patients after treatment completion. The median follow-up time of all patients was 42 months (range: 4–129 months). No patient developed local recurrence. The 5-year overall survival, regional failure-free survival, distant metastasis-free survival, and progression-free survival probabilities were 84.1%, 95.6%, 75.3%, and 75.7%, respectively. Distant metastasis was observed in 18 (20.5%) patients, followed by regional 2 (2.3%) recurrence. Permanent facial nerve injury was confirmed in 31 patients by follow-up. None of the patients experienced facial nerve paralysis in the definitive radiotherapy group.

Conclusions

LECs may be sensitive to chemoradiotherapy, which may achieve a radical effect and avoid unnecessary surgical injury. IC combined with CCRT is expected to become a new treatment strategy for advanced LECs. The IMRT target volume delineation according to the surgical principles may be a more promising method with good clinical efficacy that is worthy of further study.

Background

Salivary gland carcinomas (SGCs) are malignant neoplasms that account for approximately 1.0–8.5% of all head and neck cancers [1][2]. Recent studies have shown that the incidence of SGC is increasing every year, while the age of onset is decreasing [3][4]. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend surgery as the primary treatment for SGCs and postoperative radiotherapy for patients with advanced-stage disease or high-risk factors [5]. The major complications of surgery include facial nerve injury, with reported incidence of 12–40% [6].

According to previous literature, lymphoepithelial carcinomas (LECs) are malignancies that have morphological features similar to those of undifferentiated nasopharyngeal carcinomas (NPCs) and occur in areas outside the nasopharynx, such as in the salivary gland, lung, and stomach [7][8][9][10]. NPCs are sensitive to chemotherapy and radiotherapy, and a radical effect can be achieved by chemoradiotherapy [11]. However, there are few reports on major salivary LECs. Radical surgery is also the primary treatment for this tumor subtype according to the NCCN guidelines. In addition, LECs often invade the facial nerve due to a high malignancy degree. For this reason, some surgical scholars believe that facial nerve preservation will affect the safety of surgery and thus advocate for the removal of the involved facial nerve to reduce local recurrence [12]. In short, surgery will likely cause permanent damage to the facial nerve in addition to disfigurement, which might affect patients’ quality of life and self-confidence.
Intensity-modulated radiotherapy (IMRT) has become the standard treatment technique for head and neck cancer. However, there are few studies on target volume delineation for SGCs. Previous recommendations have determined the IMRT target volume based on the “tumor bed”, “surgical bed”, or even “parotid bed” [13][14][15]. However, our prior study suggests that these recommendations may not consider individual subtleties associated with the exact location of the primary lesion [16]. They also did not make full use of the IMRT advantage, which is that the high-dose areas conform closely to the three-dimensional shape and scale of the tumor.

Based on these considerations, the present retrospective study summarized the clinical characteristics of SGCs and analyzed failure patterns in patients treated with IMRT to provide a reference for individualized SGC treatment.

**Methods And Materials**

**Patients**

A total of 96 patients with SGCs were retrospectively evaluated between August 2009 and August 2020. The patients were restaged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for major salivary glands. The exclusion criteria were as follows: (1) evidence of distant metastasis before treatment, secondary malignancy, or both; (2) non-epithelial tumors. The ethics committee of Sun Yat-sen University Cancer Center approved the study protocol.

**Diagnosis**

All patients underwent a comprehensive exam and evaluation that included computed tomography (CT) or magnetic resonance imaging (MRI) of the head and neck, chest radiography, abdominal ultrasonography, emission computed tomography, or positron emission tomography-computed tomography. Some patients also underwent color Doppler ultrasound imaging of the salivary glands. The final diagnosis was based on histopathology or cytopathology results. Due to the histological finding similarity, distinguishing LECs from lymph nodes containing NPC metastases was especially important. Nasopharyngoscopy was conducted in all patients in order to make a correct diagnosis.

**Chemotherapy**

The induction chemotherapy (IC) regimen was a combination of taxanes, cisplatin, and fluorouracil (TPF), comprising intravenous infusion of docetaxel at a dose of 50 mg/m² on day 1, intravenous infusion of cisplatin at a dose of 60 mg/m² on day 1, and continuous intravenous infusion of 5-fluorouracil at a dose of 500 mg/m²/day on days 1–5 for 120 h, three times per week, for a total of four cycles. If tumor shrinkage achieved a partial response (PR) or above after two cycles of IC, patients continued IC for up to four cycles and were administered concurrent chemoradiotherapy (CCRT). Otherwise, the patients received CCRT after two cycles of IC or were reconsidered for surgery. CCRT treatment prescribed cisplatin at a dose of 30 mg/m² of intravenous infusion on day 1, for 4–6 cycles weekly [17].

**Radiotherapy**

Definitive radiotherapy: prior to radiotherapy, patients were immobilized with head-and-neck thermoplastic masks in a supine position. A CT simulation was then performed using 3-mm slices of the head and neck within 1–2 weeks after IC [17].

Postoperative radiotherapy: postoperative MRI of the head and neck was performed 3 weeks after surgery when the wound had healed. The patients were immobilized in a supine position with a head-and-neck thermoplastic mask [16].

Some patients were immobilized with a bolus to the skin if necessary.

**Target volume delineation**

Definitive radiotherapy: gross tumor volume of primary site/regional lymph node (GTVp/nd) was defined as the volume of the primary tumor including lymph node metastasis. Medium risk clinical tumor volume (CTV1) was defined as GTVp/nd plus a
A 0.5- to 1.0-cm margin. Low-risk CTV (CTV2) was defined as CTV1 plus a 5-mm margin together with the regional selective lymph drainage areas. According to prior studies, ipsilateral level Ib–V a should be included in parotid gland cases, ipsilateral level I–V a should be included in submandibular gland cases, and bilateral level I–V a should be included in sublingual gland cases [18][19][20]. For patients with advanced-stage disease, the GTVp/nd was contoured according to the tumor regression after IC [17].

Postoperative radiotherapy: among the reserved tissues, those located <5 mm from the invasive tumor edge before surgery were defined as high-risk CTV (CTV-HD); those located <10 mm away were defined as CTV1; and those located 10–20 mm away together with the regional selective lymph drainage areas were defined as CTV2 [16]. Examples of target volume delineation are presented in Figure 1.

Normal structures, including the mandible, brainstem, temporal lobe, oral cavity, middle ear, and spinal cord, were also contoured slice-by-slice in the treatment-planning CT scans [17].

Planning target volumes (PTV) were generated by addition of a 3–5-mm margin to all GTV/CTV values [17]. Table 1 summarizes the target volume definitions.

| Target | Definitive IMRT | Postoperative IMRT |
|--------|-----------------|---------------------|
| GTV/CTVHD | Gross tumor and positive lymph node after IC | Reserved tissues around the margin of resection that were less than 5 mm from the invasive tumor edge before surgery |
| CTV1 | GTV plus a 5- to 10-mm margin together with the primary tumor region before IC | Reserved tissues around the margin of resection that were less than 10 mm from the invasive tumor edge before surgery |
| CTV2 | CTV1 plus a 5-mm margin together with the elective nodal regions | Elective nodal regions and reserved tissues around the margin of resection that were less than 20 mm from the invasive tumor edge before surgery |

**Abbreviations:** IMRT = intensity-modulated radiotherapy; GTV = gross tumor volume; CTV = clinical target volume; IC = induction chemotherapy

**Dose prescription and delivery**

All patients enrolled since September 2015 were treated with adaptive re-planning intensity-modulated radiotherapy (AR-IMRT) after 25 fractions, while the rest of the patients were treated with one-course IMRT. The prescribed doses were GTV, 68–70 Gy; CTV-HD and CTVnd, 63–65 Gy; CTV1, 59–61 Gy; and CTV2, 45–54 Gy. The aim was to achieve 95% of any PTV at or above the prescription dose. IMRT was given once daily, 5 days per week with no treatment break [48].

**Follow-up**

The follow-up time was until August 2021 or the date of death. Treatment failure was confirmed by biopsy. Failure was defined in accordance with the definition provided by Chao et al. [21].

**Statistical analysis**

Estimates of overall survival (OS), regional failure-free survival (RFFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) were obtained using the Kaplan-Meier method. Statistical calculations were performed using SPSS version 25.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA).

**Results**
Patient characteristics

Eight patients were excluded from the analysis due to development of distant metastases during treatment or diagnosis of non-epithelial tumors. As a result, a total of 88 patients with SGCs were selected for analysis of clinicopathological profiles: 33 females (37.5%) and 55 males (62.5%). The onset age ranged from 18 to 77 years, and the median age was 45 years. The primary tumor sites were as follows: parotid gland in 61 (69.3%) patients, submandibular gland in 21 (23.9%) patients, and sublingual gland in six (6.8%) patients. LEC was the most common tumor subtype (23.9%). The type of surgery was determined by surgeons. A total of 80 (90.9%) patients received radical surgery with or without neck dissection combined with postoperative radiotherapy. Eight patients (9.1%) received definitive radiotherapy: six patients with advanced-stage disease received IC combined with concurrent CCRT, and two patients with early-stage disease received CCRT. The details of patient and tumor characteristics are summarized in Table 2.
|                     | Patients (N=88) | Definitive IMRT (N=8) | Postoperative IMRT (N=80) |
|---------------------|----------------|-----------------------|---------------------------|
| Primary site        |                |                       |                           |
| Parotid gland       | 61             | 6                     | 55                        |
| Submandibular gland | 21             | 2                     | 19                        |
| Sublingual gland    | 6              | 0                     | 6                         |
| Age, y (range)      | Median, 45 y (18−77 y) | Median, 47.5 y (27−61 y) | Median, 45 y (18−77 y)    |
| < 60                | 63             | 7                     | 56                        |
| ≥ 60                | 25             | 1                     | 24                        |
| Sex                 |                |                       |                           |
| Male                | 55             | 5                     | 50                        |
| Female              | 33             | 3                     | 30                        |
| Disease presentation|                |                       |                           |
| Primary             | 74             | 8                     | 66                        |
| Recurrent           | 14             | 0                     | 14                        |
| Histology           |                |                       |                           |
| Lymphoepithelial carcinoma (23.9 %) | 21 | 6 | 15 |
| Adenoid cystic carcinoma (20.5%) | 18 | 0 | 18 |
| Mucoepidermoid carcinoma (15.9%) | 14 | 0 | 14 |
| Salivary duct carcinoma (15.9%) | 14 | 0 | 14 |
| Acinic cell carcinoma (9.1%) | 8 | 0 | 8 |
| Squamous cell carcinoma (8.0%) | 7 | 2 | 5 |
| Other (6.8%)        | 6              | 0                     | 6                         |
| Surgery type        |                |                       |                           |
| Total parotidectomy | 23             | 0                     | 23                        |
| Superficial parotidectomy | 23 | 0 | 23 |
| Submandibular gland excision | 19 | 0 | 19 |
| Sublingual gland excision | 5 | 0 | 5 |
| Unoperated          | 8              | 8                     | 0                         |
| Not Available*      | 10             | 0                     | 10                        |
| Treatment type      |                |                       |                           |

Abbreviations: IMRT = intensity-modulated radiotherapy; IC = induction chemotherapy; CCRT = concurrent chemoradiotherapy; S = surgery; RT = radiotherapy; AR-IMRT = adaptive re-planning intensity-modulated radiotherapy

*Patients received surgery in another center and their operation records could not be found.
| Radiotherapy type | Patients (N=88) | Definitive IMRT (N=8) | Postoperative IMRT (N=80) |
|-------------------|----------------|----------------------|--------------------------|
| IC+CCRT           | 6              | 6                    | 0                        |
| CCRT              | 2              | 2                    | 0                        |
| S+CCRT            | 62             | 0                    | 62                       |
| S+RT              | 18             | 0                    | 18                       |

Radiotherapy type

| One-course | 40 | 2 | 38 |
| AR-IMRT    | 48 | 6 | 42 |

Abbreviations: IMRT = intensity-modulated radiotherapy; IC = induction chemotherapy; CCRT = concurrent chemoradiotherapy; S = surgery; RT = radiotherapy; AR-IMRT = adaptive re-planning intensity-modulated radiotherapy

*Patients received surgery in another center and their operation records could not be found.

**Efficacy**

After completion of definitive radiotherapy, complete response (CR) was observed in all of the patients. Table 3 summarizes clinical characteristics and outcomes of these eight patients. Cases 1–3 have been previously described by our team [22]. Updated follow-up data showed that Cases 1 and 2 were still alive without evidence of disease, while Case 3 died of distant metastasis. Case 6 was a 52-year-old man who achieved a PR after IC. After completion of definitive radiotherapy, CR was observed via MRI, and the patient showed no evidence of disease until the last follow-up (2021-8). Details of Case 6 are presented in Figure 2.
Table 3
Details of patients received definitive IMRT

| Case1 | Case2 | Case3 | Case4 | Case5 | Case6 | Case7 | Case8 |
|-------|-------|-------|-------|-------|-------|-------|-------|
| Primary site | Parotid gland | Parotid gland | Submandibular gland | Parotid gland | Parotid gland | Parotid gland | Submandibular gland |
| Age, y | 27 | 33 | 52 | 61 | 44 | 52 | 37 | 54 |
| Sex | Male | Male | Male | Male | Female | Male | Female | Female |
| Histology | LEC | LEC | LEC | LDSCC | LDSCC | LEC | LEC | LEC |
| Stage | T4N3M0 | T4N3M0 | T4N2M0 | T4N2M0 | T4N2M0 | T4N2M0 | T1N0M0 | T1N0M0 |
| Regimen | TPF for 4 cycles plus DDP | CCRT | DDP CCRT |

| RT type | AR-IMRT | AR-IMRT | AR-IMRT | One-course | AR-IMRT | One-course | AR-IMRT | AR-IMRT |
|---------|---------|---------|---------|------------|---------|------------|---------|---------|
| Overall survival time, m | 28+ | 73+ | 15 | 100+ | 79+ | 35+ | 20+ | 20+ |
| Died of distant metastasis | | | | | |

| Progression-free survival time, m | 28+ | 73+ | 13 | 100+ | 79+ | 35+ | 20+ | 20+ |

Abbreviations: LEC = lymphoepithelial carcinoma; LDSCC = low differentiated squamous cell carcinoma; TPF = taxanes, cisplatin and fluorouracil; DDP = cisplatin; CCRT = concurrent chemoradiotherapy; RT = radiotherapy; AR-IMRT = adaptive replanning intensity-modulated radiotherapy

The median follow-up time for SGC patients was 42 months (range: 4–129 months). During follow-up, primary recurrence included local recurrence in 0 (0.0%) patients and regional recurrence in two (2.3%) patients. Distant metastasis was observed in 18 patients (20.5%). The five-year OS, RFFS, DMFS, and PFS rates were 84.1%, 95.6%, 75.3%, and 75.7%, respectively (Figure 3).

Clinical characteristics of the two patients with regional failure are summarized in Table 4.

Table 4
Details of patients with regional failure

| Primary site | Histology | Stage | Surgery type | Failure site | Patterns of failure | Isodose (Gy) | Disease-free time, m |
|--------------|-----------|-------|--------------|--------------|--------------------|--------------|---------------------|
| Parotid gland | SCC | T4bN2M0 | Total parotidectomy | Ipsilateral level | PCTV2/50 | 55.29 | 62 |
| Submandibular gland | SCC | T2N2M0 | Submandibular gland excision | Ipsilateral level II | PCTV2/45 | 54.77 | 13 |

Abbreviations: SCC = squamous cell carcinoma

Supplementary Table 1. Comparison of tumor volume before and after IC

The pre-RT MRI showed an insignificantly enlarged lymph node that did not meet the diagnostic criteria in both cases, which were contoured in CTV2 (Figure 4–5).

Treatment Toxicity
Thirty-one patients who received surgery experienced peripheral facial paralysis. The relationship between facial paralysis and SGC subtypes is shown in Figure 6. LECs with facial paralysis accounted for 7/12 patients (58.3%), and other pathological types accounted for 19/63 patients (30.2%). Eight patients without surgery had an intact facial nerve and a normal appearance without reconstruction. In addition, Case 2 was a 33-year-old man who was admitted with a slowly growing mass in the left periauricular region and facial paresis. Six months after definitive radiotherapy, the patient's facial nerve function was fully recovered.

During IC (N=6), only one patient developed Grade 3 leukopenia. CCRT (N=70) induced several severe toxic effects, such as Grade 3 dermatitis (2/70, 2.8%), Grade 3 mucositis (5/70, 7.1%), Grade 3 xerostomia (3/70, 4.3%), and Grades 3–4 leukopenia (10/70, 14.3%). None of the patients experienced cholesteatoma otitis media, trismus, skin ulceration, mandibular osteoradionecrosis, or radiation encephalopathy.

**Discussion**

Histological classification of SGCs is very demanding and 24 subtypes have been specified according to the World Health Organization classification of malignant salivary gland tumors [23]. In 666 patients with SGCs in a study performed in the Netherlands, for which the pathology results were revised, adenoid cystic carcinoma (27%) was the most frequently diagnosed, followed by mucoepidermoid carcinoma (16%) and acinic cell carcinoma (14%) [24]. No satisfactory chemoradiotherapy method for the above tumor subtypes has been reported, while surgery was considered to be a more effective treatment [5][25]. High local failure rates of approximately 40% for parotid and 60% for submandibular tumors were observed with surgery alone [26]. Patients with advanced-stage disease or high-risk factors were recommended for postoperative radiotherapy [5][25]. IMRT has become the standard technique for SGC radiotherapy, enhancing local control by 80–95% [18][27][28][29]. However, surgery is likely to cause permanent damage to facial nerve function in addition to disfigurement, which could affect the patients’ quality of life and self-confidence. Facial paralysis accounted for 31/80 patients (35.2%) in the present study, which is similar to a previous report [6]. In addition, LEC with facial paralysis accounted for 7/12 patients (58.3%), suggesting that LECs often invade the facial nerve due to a high malignancy degree.

LEC has distinct racial and regional characteristics and is well known to occur in a limited number of patients in the localized regions of Southwest Asia, southern parts of China, and the Arctic Circle [30][31]. In 235 patients with SGCs in a study performed in China, LECs were diagnosed in 21.2% of the cohort, which is a much higher rate than the reported average incidence of this disease in the western world [32]. Results of the present study are similar to this previous report (21/88, 23.9%). LEC is an undifferentiated carcinoma, which lacks obvious cell differentiation [7]. And LECs have similarities to NPCs in histological appearance, relationship with Epstein-Barr virus and race, and response to treatment [33][34][35]. Chemoradiotherapy is considered to be the first choice of treatment for NPCs. According to prior literature, IC plus CCRT in locoregionally advanced NPC showed a remarkable 5-year PFS (77.4%), OS (85.6%), DMFS (88.0%), and locoregional failure-free survival (90.7%). LEC is a rare malignant tumor that is typically treated with surgery according to previous recommendations. Although few clinical trials have been designed to investigate the efficacy of systemic therapy because of the rarity of the disease, some scholars have suggested that chemotherapy and radiotherapy may be of benefit as well. Praveen et al. have suggested that systemic therapy was a reasonable approach for patients who presented with regional adenopathy because they have a relatively high rate of distant metastasis [36]. There are also few chemotherapy regimens available for LEC treatment [37][38][39]. The present study reviewed the literature concerning LEC in the salivary gland and found two reports of patients treated without surgery. Kaidar-Person et al. have reported a case of LEC in the parotid gland that was effectively treated with a single cycle of chemotherapy followed by radiotherapy, with no evidence of disease 4 years after treatment [40]. Maeda et al. have reported a case of LEC in the parotid gland that was effectively treated with CCRT, with no evidence of disease 5 years after treatment [41].

The present study included 21 LEC cases. Influenced by the NCCN guidelines, surgical cases accounted for 15/21 patients (71.4%). Only six patients with LECs and two patients with low differentiated squamous cell carcinomas received definitive chemoradiotherapy. CR was observed in these eight cases, and all of these patients had an intact facial nerve. Consequently, to avoid facial nerve injury, chemoradiotherapy is a better choice for SGCs with poor differentiation, especially LECs.
There is still confusion concerning the optimal radiation target volume for SGCs. As reported previously, the present study relied on surgical principles to determine the IMRT target volume [16]. The 5-year OS, RFFS, DMFS, and PFS were 84.1%, 95.6%, 75.3%, and 75.7%, respectively. No patient developed local recurrence, and the main cause of failure within the study cohort was distant metastasis, which suggested that the method was reasonable and worthy of further research.

The present study included 14 patients with recurrent SGCs after primary surgery. In general, the first treatment plays a major role in cancer. But perhaps because of the special anatomic location of the salivary glands, secondary operation plus postoperative radiotherapy for recurrent SGCs also showed good clinical outcomes. Consequently, patients with recurrent SGCs are expected to strive for radical treatment.

The pre-RT MRI showed an insignificantly enlarged lymph node that did not meet the diagnostic criteria for both regional failures, which were contoured in CTV2 (Figure 4–5). According to a previous report, high rates of implicit metastasis of approximately 12–45% were observed for lymph nodes in SGCs cases, suggesting that it is very important in clinical practice to determine whether the lymph nodes have been spared or not [42][43]. However, the optimal treatment for risky lymph nodes that do not meet the diagnostic criteria remains to be determined. Guidelines from the NCCN recommend prescription doses of 44–50 Gy and 54–63 Gy for low and intermediate risk sites of suspected subclinical spread, respectively [5]. In addition, recurrence observed in a previous study occurred in a cervical lymph node that was not significantly enlarged, but was probably involved, and received a radiation dose of about 64 Gy [44]. Consequently, to control the more than microscopic disease, a dose of 63-65 Gy has been irradiated for the risky lymph nodes in the following treatment.

The present study has some limitations. First, it was a retrospective study from a single center, and further prospective multicenter studies are needed. Second, patients without surgery received lesion site fine needle aspiration biopsy in our study. According to previous reports, fine needle aspiration biopsy showed a sensitivity and a specificity of 41.7–92.8% and 93.9–98.5%, respectively [45][46][47]. Whether intraoperative frozen sections should be performed to obtain more pathological information is need to be studied further.

Conclusions

LECs may be sensitive to chemoradiotherapy, which may achieve a radical effect and avoid unnecessary surgical injury. IC combined with CCRT is expected to become a new treatment strategy for advanced LECs. The IMRT target volume delineation according to the surgical principles may be a more promising method with good clinical efficacy that is worthy of further study.

Abbreviations

IMRT: intensity-Modulated Radiotherapy, SGC: major salivary gland carcinoma, LEC: lymphoepithelial carcinoma, IC: induction chemotherapy, CCRT: concurrent chemoradiotherapy, NCCN: National Comprehensive Cancer Network, NPC: nasopharyngeal carcinoma, AJCC: American Joint Committee on Cancer, CT: computed tomography, MRI: magnetic resonance imaging, TPF: taxanes, cisplatin, and fluorouracil, GTVp/nd: gross tumor volume of primary site/regional lymph node, CTV1: medium risk clinical tumor volume, CTV2: low risk clinical tumor volume, CTV-HD: high-risk clinical tumor volume, PTV: planning target volumes, OS: overall survival, RFFS: regional failure-free survival, DMFS: distant metastasis-free survival, PFS: progression-free survival, CR: complete response, PR: partial response

Declarations

Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee of Affiliated Hospital of Sun Yat-sen University Cancer Center, and the need for written informed consent was waived.

Consent for publication: Not applicable.

Availability of supporting data and materials: All data generated or analyzed during this study are included in this published article.
Competing interests: The authors declare that they have no competing interests.

Authors’ Contributions: ZQ YS: conception and design; ZQ WC FL SL XL: data collection, statistical analysis; ZQ ZW: manuscript preparation; ZW LW DX: manuscript editing; YT YS: quality control of data and manuscript review; MW JH: radiation therapy planning.

All authors read and approved the final manuscript.

Acknowledgments: The authors declare that they have no funding.

References
1. Bjørndal K, Krogdahl A, Therkildsen M H, et al. Salivary gland carcinoma in Denmark 1990–2005: Outcome and prognostic factors: Results of the Danish Head and Neck Cancer Group (DAHANCA)[J]. Oral Oncology, 2012, 48(2): 179-185.
2. Gatta G, Guzzo M, Locati L D, et al. Major and minor salivary gland tumours[J]. Critical Reviews in Oncology/Hematology, 2020, 152: 102959.
3. Del Signore A G, Megwalu U C. The rising incidence of major salivary gland cancer in the United States[J]. Ear, Nose & Throat Journal, 2017, 96(3): E13-E16.
4. Ata-Ali J, Zurriaga O, Alberich C. Incidence and survival rates for malignant salivary gland tumors[J]. Journal of Oral Science, 2016, 58(1): 67-73.
5. National Comprehensive Cancer Network. Head and Neck Cancers (Version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed April 27, 2021.
6. Guntinas-Lichius O, Silver C E, Thielker J, et al. Management of the facial nerve in parotid cancer: preservation or resection and reconstruction[J]. European Archives of Oto-rhino-laryngology, 2018, 275(11): 2615-2626.
7. Hilderman W C, Gordon J S, Large Jr H L, et al. Malignant lymphoepithelial lesion with carcinomatous component apparently arising in parotid gland. A malignant counterpart of benign lymphoepithelial lesion?[J]. Cancer, 1962, 15(3): 606-610.
8. Saku T, Cheng J, Jen K Y, et al. Epstein-Barr virus infected lymphoepithelial carcinomas of the salivary gland in the Russia-Asia area: a clinicopathologic study of 160 cases[J]. Arkhiv Patologii, 2003, 65(2): 35-39.
9. Pittaluga S, Wong M P, Chung L P, et al. Clonal Epstein-Barr virus in lymphoepithelioma-like carcinoma of the lung[J]. The American Journal of Surgical Pathology, 1993, 17(7): 678-682.
10. Shibata D, Tokunaga M, Uemura Y, et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma[J]. The American Journal of Pathology, 1991, 139(3): 469.
11. Li W F, Chen N Y, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long–term results of phase 3 randomized controlled trial[J]. International Journal of Cancer, 2019, 145(1): 295-305.
12. Whelan A, Al-Sayed A A, Bullock M, et al. Primary parotid lymphoepithelial carcinoma: A case report and literature review of a rare pathological entity[J]. International Journal of Surgery Case Reports, 2020, 72: 610-614.
13. Kaur J, Goyal S, Muzumder S, et al. Outcome of surgery and post-operative radiotherapy for major salivary gland carcinoma: ten year experience from a single institute[J]. Asian Pacific Journal of Cancer Prevention, 2014, 15(19): 8259-8263.
14. Hosni A, Huang S H, Goldstein D, et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy[J]. Oral Oncology, 2016, 54: 75-80.
15. Nutting C M, Morden J P, Beasley M, et al. Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)[J]. European Journal of Cancer, 2018, 103: 249-258.
16. Lyu S, Wu Z, Xie D, et al. Clinical target volume delineation of postoperative intensity-modulated radiotherapy for major salivary gland tumours according to surgical principles: an innovative method[J]. Journal of Cancer Research and Clinical Oncology, 2021: 1-10.
17. Wang L, Wu Z, Xie D, et al. Reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma[J]. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 2019, 51(2): 685.
18. Terhaard C H J, Lubsen H, Rasch C R N, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors[J]. International Journal of Radiation Oncology* Biology* Physics, 2005, 61(1): 103-111.
19. Ferlito A, Pellitteri P K, Robbins K T, et al. Management of the neck in cancer of the major salivary glands, thyroid and parathyroid glands[J]. Acta Oto-laryngologica, 2002, 122(6): 673-678.
20. Armstrong J G, Harrison L B, Thaler H T, et al. The indications for elective treatment of the neck in cancer of the major salivary glands[J]. Cancer, 1992, 69(3): 615-619.
21. Chao K S C, Ozyigit G, Tran B N, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer[J]. International Journal of Radiation Oncology* Biology* Physics, 2003, 55(2): 312-321.
22. Lv S, Xie D, Wu Z, et al. Is surgery an inevitable treatment for advanced salivary lymphoepithelial carcinoma? Three case reports[J]. Ear, Nose & Throat Journal, 2020: 0145561320923170.
23. Leivo I. Insights into a complex group of neoplastic disease: advances in histopathologic classification and molecular pathology of salivary gland cancer[J]. Acta Oncologica, 2006, 45(6): 662-668.
24. Terhaard C H J, van der Schroeff M P, van Schie K, et al. The prognostic role of comorbidity in salivary gland carcinoma[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2008, 113(7): 1572-1579.
25. Geiger J L, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO Guideline[J]. Journal of Clinical Oncology, 2021: JCO. 21.00449.
26. Spiro R H. Salivary neoplasms: overview of a 35-year experience with 2,807 patients[J]. Head & Neck Surgery, 1986, 8(3): 177-184.
27. Therkildsen M H, Christensen M, Andersen L J, et al. Salivary gland carcinomas: Prognostic factors[J]. Acta Oncologica, 1998, 37(7-8): 701-713.
28. Chen A M, Bucci M K, Weinberg V, et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: Prognostic features of recurrence[J]. International Journal of Radiation Oncology* Biology* Physics, 2006, 66(1): 152-159.
29. Poulsen M G, Pratt G R, Kynaston B, et al. Prognostic variables in malignant epithelial tumors of the parotid[J]. International Journal of Radiation Oncology* Biology* Physics, 1992, 23(2): 327-332.
30. Nielsen N H Ø, Mikkelsen F, Hansen J P H. Incidence of salivary gland neoplasms in Greenland with special reference to an anaplastic carcinoma[J]. Acta Pathologica Microbiologica Scandinavica Section A Pathology, 1978, 86(1-6): 185-193.
31. Leung S Y, Chung L P, Yuen S T, et al. Lymphoepithelial carcinoma of the salivary gland: in situ detection of Epstein-Barr virus[J]. Journal of Clinical Pathology, 1995, 48(11): 1022-1027.
32. Li F, Zhu G, Wang Y, et al. A clinical analysis of 37 cases with lymphoepithelial carcinoma of the major salivary gland treated by surgical resection and postoperative radiotherapy: A single institution study[J]. Medical Oncology, 2014, 31(5): 957.
33. Cleary K R, Batsakis J G. Undifferentiated carcinoma with lymphoid stroma of the major salivary glands[J]. Annals of Otology, Rhinology & Laryngology, 1990, 99(3): 236-238.
34. Hamilton-Dutoit S J, Therkildsen M H, Nielsen N H, et al. Undifferentiated carcinoma of the salivary gland in Greenlandic Eskimos: demonstration of Epstein-Barr virus DNA by in situ nucleic acid hybridization[J]. Human Pathology, 1991, 22(8): 811-815.
35. Lanier A P, Clift S R, Bornkamm G, et al. Epstein-Barr virus and malignant lymphoepithelial lesions of the salivary gland[J]. Arctic Medical Research, 1991, 50(2): 55-61.
36. Dubey P, Ha C S, Ang K K, et al. Nonnasopharyngeal lymphoepithelioma of the head and neck[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1998, 82(8): 1556-1562.

37. Zhang Q, Qing J, Wei M W, et al. Clinical analysis of sixteen cases of lymphoepithelial carcinoma of salivary gland[J]. Ai zheng= Aizheng= Chinese Journal of Cancer, 2005, 24(11): 1384-1387.

38. Wang C P, Chang Y L, Ko J Y, et al. Lymphoepithelial carcinoma versus large cell undifferentiated carcinoma of the major salivary glands[J]. Cancer, 2004, 101(9): 2020-2027.

39. Sun X, Jing X U, Yang Q, et al. Lymphoepithelioma-like carcinoma of the submandibular salivary gland: a case report[J]. Chinese Medical Journal, 2006, 119(15): 1315-1317.

40. Kaidar-Person O, Kuten A, Billan S. Lymphoepithelioma-like carcinoma of the salivary gland: is radiotherapy alone adequate?[J]. Case reports in otolaryngology, 2011, 2011.

41. Maeda H, Yamashiro T, Yamashita Y, et al. Lymphoepithelial carcinoma in parotid gland related to EBV infection: A case report[J]. Auris Nasus Larynx, 2018, 45(1): 170-174.

42. Armstrong J G, Harrison L B, Thaler H T, et al. The indications for elective treatment of the neck in cancer of the major salivary glands[J]. Cancer, 1992, 69(3): 615-619.

43. Chisholm E J, Elmiyeh B, Dwivedi R C, et al. Anatomic distribution of cervical lymph node spread in parotid carcinoma[J]. Head & Neck, 2011, 33(4): 513-515.

44. Kwong D L W, Pow E H N, Sham J S T, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function[J]. Cancer, 2004, 101(7): 1584-1593.

45. Shkedy Y, Alkan U, Mizrachi A, et al. Fine-needle aspiration cytology for parotid lesions, can we avoid surgery?[J]. Clinical Otolaryngology, 2018, 43(2): 632-637.

46. Henrys C E, Grigg R. Use of fine-needle aspiration cytology in the diagnosis of parotid neoplasms[J]. ANZ Journal of Surgery, 2015, 85(11): 838-842.

47. Dostalova L, Kalfert D, Jechova A, et al. The role of fine-needle aspiration biopsy (FNAB) in the diagnostic management of parotid gland masses with emphasis on potential pitfalls[J]. European Archives of Oto-Rhino-Laryngology, 2020, 277(6): 1763-1769.

48. Xie D, Cheng W, Lv S, et al. Target delineation and dose prescription of adaptive replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Cancer Communications, 2019, 39(1): 1-4.

### Supplementary Table

**Supplementary Table 1. Comparison of tumor volume before and after IC**

|                | GTV-PRE (cm³) | GTV-POST (cm³) | GTV shrinkage | GTVnd-PRE (cm³) | GTVnd-POST (cm³) | GTVnd shrinkage |
|----------------|---------------|----------------|---------------|-----------------|------------------|----------------|
| Case1          | 174.879       | 74.871         | 57.2%         | 26.961          | 6.072            | 77.5%          |
| Case2          | 36.369        | 18.744         | 48.5%         | 22.659          | 9.741            | 57.0%          |
| Case3          | 140.092       | 71.627         | 49.2%         | 30.102          | 11.940           | 60.3%          |
| Case4          | 99.72         | 46.027         | 46.4%         | 22.707          | 6.918            | 69.5%          |
| Case5          | 34.833        | 21.741         | 37.6%         | 8.913           | 2.925            | 67.2%          |
| Case6          | 129.972       | 52.812         | 59.4%         | 27.669          | 8.940            | 67.7%          |

Abbreviations: GTV-PRE = gross tumor volume before induction chemotherapy; GTV-POST = gross tumor volume after induction chemotherapy; GTVnd-PRE = gross tumor volume of regional lymph node before induction chemotherapy; GTVnd-POST = gross tumor volume of regional lymph node after induction chemotherapy.
Supplementary Table 2. AJCC 8th stage distribution of 88 patients

|                  | Patients N=88 | Definitive IMRT N=8 | Postoperative IMRT N=80 |
|------------------|---------------|---------------------|-------------------------|
| T Classification |               |                     |                         |
| T1               | 10            | 2                   | 8                       |
| T2               | 22            | 0                   | 22                      |
| T3               | 13            | 0                   | 13                      |
| T4               | 21            | 6                   | 15                      |
| N Classification |               |                     |                         |
| N0               | 15            | 2                   | 13                      |
| N1               | 14            | 0                   | 14                      |
| N2               | 30            | 4                   | 26                      |
| N3               | 7             | 2                   | 5                       |
| Not Available*   | 22            | 0                   | 22                      |

*In total of 22 patients received surgery in another center and their preoperative CT could not be found.

**Figures**
Figure 1

Target volume delineation of postoperative radiotherapy for salivary gland cancer patients. (A) Preoperative CT showed that the tumor (redline) crossed the deep lobe and the isthmus of the parotid gland and was adjacent to posterior venter of the digastric muscle, carotid sheath, styloid process and mandibular branch; (B) Surgical records showed that the patient underwent partial parotidectomy and facial nerve dissection. The purple dotted line showed the extent of surgical resection; (C) Postoperative MR showed that the reserved tissues included the retained parotid tissues (blue line), posterior venter of the digastric muscle, carotid sheath, styloid process and mandibular branch. (D) Posterior venter of the digastric muscle, carotid sheath, styloid process and mandibular branch were all less than 5 mm from the primary tumor edge, so they were very likely to be invaded, as delineated in the CTV-HD area. The retained parotid tissues were more than 10 mm away from the primary tumor edge, so they were delineated in the CTV2 area.
Figure 2

Details of Case 6. (A) Before induction chemotherapy (IC); (B) After IC, partial response was achieved; (C) After chemoradiotherapy, complete response was achieved; (D) Target volume delineation of definitive radiotherapy for Case 6; (E) Dose color wash; (F) DVH.
Figure 3

(A) Kaplan-Meier estimates of overall survival (5-year OS, 84.1%; 95% CI, 95.05 to 116.37); (B) Kaplan-Meier estimates of regional failure-free survival (5-year RFFS, 95.6%; 95% CI, 120.55 to 130.34); (C) Kaplan-Meier estimates of distant metastasis-free survival (5-year DMFS, 75.3%; 95% CI, 91.63 to 113.39); (D) Kaplan-Meier estimates of progression-free survival (5-year PFS, 75.7%; 95% CI, 91.66 to 113.39).
Figure 4

(A) Postoperative MR showed a lymph node measuring 6 mm; (B) The patient complained of a palpable node after 5 years, and regional recurrence was finally diagnosed; (C) Target volume delineation of postoperative radiotherapy; (E) Dose color wash; (F) DVH.

Figure 5
(A) Postoperative CT showed a lymph node measuring 4 mm; (B) Regional recurrence was finally diagnosed by CT after 2 years; (C) Target volume delineation of postoperative radiotherapy; (E) Dose color wash; (F) DVH.

**Figure 6**

The relationship between facial paralysis and SGCs subtypes. Abbreviations: LEC = lymphoepithelial carcinoma

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure1.png](#)